68 related articles for article (PubMed ID: 16157762)
1. Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease.
Borghammer P; Kumakura Y; Cumming P
Arch Neurol; 2005 Sep; 62(9):1480; author reply 1480-1. PubMed ID: 16157762
[No Abstract] [Full Text] [Related]
2. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
Hilker R; Schweitzer K; Coburger S; Ghaemi M; Weisenbach S; Jacobs AH; Rudolf J; Herholz K; Heiss WD
Arch Neurol; 2005 Mar; 62(3):378-82. PubMed ID: 15767502
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.
Leenders KL; Poewe WH; Palmer AJ; Brenton DP; Frackowiak RS
Ann Neurol; 1986 Aug; 20(2):258-62. PubMed ID: 3092728
[TBL] [Abstract][Full Text] [Related]
4. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging.
Eckert T; Feigin A; Lewis DE; Dhawan V; Frucht S; Eidelberg D
Mov Disord; 2007 Jan; 22(2):167-73. PubMed ID: 17133454
[TBL] [Abstract][Full Text] [Related]
5. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
Herzog CD; Dass B; Holden JE; Stansell J; Gasmi M; Tuszynski MH; Bartus RT; Kordower JH
Mov Disord; 2007 Jun; 22(8):1124-32. PubMed ID: 17443702
[TBL] [Abstract][Full Text] [Related]
6. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates.
Pate BD; Snow BJ; Hewitt KA; Morrison KS; Ruth TJ; Calne DB
J Nucl Med; 1991 Jun; 32(6):1246-51. PubMed ID: 1904482
[TBL] [Abstract][Full Text] [Related]
7. Striatal beta-amyloid deposition in Parkinson disease with dementia.
Jellinger KA
J Neuropathol Exp Neurol; 2008 May; 67(5):484; author reply 484-5. PubMed ID: 18451728
[No Abstract] [Full Text] [Related]
8. Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure.
Schiess M; Oh I
Arch Neurol; 2008 Jun; 65(6):698-9. PubMed ID: 18541788
[No Abstract] [Full Text] [Related]
9. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.
Vingerhoets FJ; Snow BJ; Lee CS; Schulzer M; Mak E; Calne DB
Ann Neurol; 1994 Nov; 36(5):759-64. PubMed ID: 7979222
[TBL] [Abstract][Full Text] [Related]
10. An aging effect in striatal fluorodopa uptake? Large versus small ROIs.
Snow BJ; Vingerhoets FJ; Martin WR
J Cereb Blood Flow Metab; 1994 Sep; 14(5):882-3. PubMed ID: 8063884
[No Abstract] [Full Text] [Related]
11. PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report.
Okada A; Nakamura K; Snow BJ; Bhatt MH; Nomoto M; Osame M; Calne DB
Adv Neurol; 1993; 60():591-4. PubMed ID: 8420196
[No Abstract] [Full Text] [Related]
12. Fuming over Parkinson disease: are welders at risk?
Martin WR
Neurology; 2011 Apr; 76(15):1286-7. PubMed ID: 21471465
[No Abstract] [Full Text] [Related]
13. Dopaminergic innervation of the human striatum in Parkinson's disease.
Papapetropoulos S; Basel M; Mash DC
Mov Disord; 2007 Jan; 22(2):286-8. PubMed ID: 17083095
[No Abstract] [Full Text] [Related]
14. Positron emission tomography in movement disorders.
Martin WR
Can J Neurol Sci; 1985 Feb; 12(1):6-10. PubMed ID: 3156662
[TBL] [Abstract][Full Text] [Related]
15. Combining high-performance liquid chromatography-positron detection and on-line microdialysis for animal metabolism study of positron emission tomography probes.
Nakao R; Okada M; Inoue O; Fukumura T; Suzuki K
J Chromatogr A; 2008 Sep; 1203(2):193-7. PubMed ID: 18674768
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography in manganese intoxication.
Wolters EC; Huang CC; Clark C; Peppard RF; Okada J; Chu NS; Adam MJ; Ruth TJ; Li D; Calne DB
Ann Neurol; 1989 Nov; 26(5):647-51. PubMed ID: 2510588
[TBL] [Abstract][Full Text] [Related]
17. Indirect-pathway neurons lose their spines in Parkinson disease.
Gerfen CR
Nat Neurosci; 2006 Feb; 9(2):157-8. PubMed ID: 16439979
[No Abstract] [Full Text] [Related]
18. [Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET].
Kato T
Rinsho Shinkeigaku; 2007 Nov; 47(11):829-31. PubMed ID: 18210809
[TBL] [Abstract][Full Text] [Related]
19. 18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson disease.
Fernandez HH; Friedman JH
Arch Neurol; 2002 Dec; 59(12):1973; author reply 1973-4. PubMed ID: 12470189
[No Abstract] [Full Text] [Related]
20. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
